If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
== History == In 1822, Baron Charles Cagniard de la Tour discovered the critical point of a substance in his famous cannon barrel experiments. Listening to discontinuities in the sound of a rolling flint ball in a sealed cannon filled with fluids at various temperatures, he observed the critical temperature. Above this temperature, the densities of the liquid and gas phases become equal and the distinction between them disappears, resulting in a single supercritical fluid phase. Recently, a significant effort has been devoted to investigation of various properties of supercritical fluids. Supercritical fluids have found application in a variety of fields, ranging from the extraction of floral fragrance from flowers to applications in food science such as creating decaffeinated coffee, functional food ingredients, pharmaceuticals, cosmetics, polymers, powders, bio- and functional materials, nanomaterials, natural products, biotechnology, fossil and bio-fuels, microelectronics, energy and environment. There have also been efforts to use supercritical fluids to improve effectiveness of sensors. The development of new experimental methods and improvement of existing ones continues to play an important role in this field, with recent research focusing on dynamic properties of fluids.
The United States Patent Office issued a ruling 8 October 1883, that Edison's patents were based on the prior art of William Sawyer and were invalid. Litigation continued for a number of years. Eventually on 6 October 1889, a judge ruled that Edison's electric light improvement claim for "a filament of carbon of high resistance" was valid. In 1893, Heinrich Göbel claimed he had designed the first incandescent light bulb in 1854, with a thin carbonized bamboo filament of high resistance, platinum lead-in wires in an all-glass envelope, and a high vacuum. Judges of four courts raised doubts about the alleged Göbel anticipation, but there was never a decision in a final hearing due to the expiration of Edison's patent. Research work published in 2007 concluded that the story of the Göbel lamps in the 1850s is fictitious. The main difficulty with evacuating the lamps was moisture inside the bulb, which split when the lamp was lit, with resulting oxygen attacking the filament. In the 1880s, phosphoric anhydride was used in combination with expensive mercury vacuum pumps. However, about 1893, Italian inventor Arturo Malignani (1865–1939), who lacked these pumps, discovered that phosphorus vapours did the job of chemically binding the remaining amounts of water and oxygen. In 1896 he patented a process of introducing red phosphorus as the so-called getter inside the bulb which allowed the production of economic bulbs lasting 800 hours; his patent was acquired by Edison in 1898.
At 7pm on January 9, Urquía Carreño called Viñas Alonso and asked if they could meet in private. Urquía Carreño brought Airán Cervera with him, and they met in Viñas Alonso's home. Urquía Carreño and Airán Cervera then informed him about the missing safe. Viñas Alonso said: "This is a very serious situation.... Did you call the police?" Urquía Carreño replied that he had not, to avoid damaging Freemasonry's image. Viñas Alonso asked why Urquía Carreño waited four days to inform him that the safe was missing, but Airán Cervera assured him that they could have the money replaced by March. "We talk all the time. You should have told me. You should have gone to the police... Just leave. I need time to think. This is all very serious." Viñas Alonso said. Urquía Carreño and Airán Cervera left. At 9pm on January 9, Viñas Alonso deliberated scheduling an urgent meeting of the Board of Trustees for the next day. He called Urquía Carreño to discuss this option. "Don't do that, it won't benefit anyone," Urquía Carreño said. Viñas Alonso then insisted the meeting would take place at 4pm. At the emergency meeting of the Board of Trustees on January 9, the Board of Trustees was made aware of the situation, and Viñas Alonso made a motion for a vote on two proposals. The first was to go immediately to the National Revolutionary Police and file a police report. The second proposal was to draft a report that would be sent out to all Cuban Freemasons detailing the events which took place.
Sources: en.wikipedia.org
=== Abuse and special populations === Benzodiazepine abuse and misuse are guarded against when prescribed to those with alcohol or other drug dependencies or who have psychiatric disorders. Pediatric patients For those less than 18 years of age, this treatment is usually not indicated, except for treatment of epilepsy, and pre-or postoperative treatment. The smallest possible effective dose is typically used for this group of patients. Under 6 months of age, safety and effectiveness have not been established; diazepam is not given to those in this age group. Elderly and seriously ill patients can experience apnea or cardiac arrest. Concomitant use of other central nervous system depressants increases this risk. The smallest possible effective dose is generally used for this group of people. The elderly metabolize benzodiazepines much more slowly than younger adults, and are also more sensitive to the effects of benzodiazepines, even at similar blood plasma levels. Doses of diazepam are recommended to be about half of those given to younger people, and treatment is limited to a maximum of two weeks. Long-acting benzodiazepines such as diazepam are not recommended for the elderly. Diazepam can also be dangerous in geriatric patients owing to a significantly increased risk of falls. Intravenous or intramuscular injections in hypotensive people or those in shock are administered carefully, and vital signs are closely monitored.
== History == Gemtuzumab ozogamicin was created in a collaboration between Celltech and Wyeth that began in 1991. The same collaboration later produced inotuzumab ozogamicin. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In the United States, gemtuzumab ozogamicin was approved under an accelerated-approval process by the FDA in 2000, for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML); or those who are not considered candidates for standard chemotherapy. The accelerated approval was based on the surrogate endpoint of response rate. It was the first antibody-drug conjugate to be approved. Within the first year after approval, the FDA required a black box warning be added to gemtuzumab packaging. The drug was noted to increase the risk of veno-occlusive disease in the absence of bone marrow transplantation. Later the onset of VOD was shown to occur at increased frequency in gemtuzumab patients even following bone marrow transplantation. The drug was discussed in a 2008 JAMA article, which criticized the inadequacy of postmarketing surveillance of biologic agents. A randomized Phase III comparative controlled trial (SWOG S0106) was initiated in 2004, by Wyeth in accordance with the FDA accelerated-approval process. The study was stopped on August 20, 2009, prior to completion due to worrisome outcomes. Among the patients evaluated for early toxicity, fatal toxicity rate was significantly higher in the gemtuzumab combination therapy group vs the standard therapy group.
=== Human mutations === 341 mutations in human OTC have been reported. At least 259 of these mutations are considered to be disease-causing mutations. 149 of these mutations are known to cause onset of hyperammonemia during the first weeks of life. 70 manifest as hyperammonemia in male patients later in life. Most of the mutations occur in known functional motifs, such as the SMG loop or CP binding domains.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.